Evidence map›Paper›PMID 39444939›Full record

ReviewMaterials today. Bio2024

Exploring the frontiers: The potential and challenges of bioactive scaffolds in osteosarcoma treatment and bone regeneration.

Huaiyuan Zhang, Yu Wang, Huifen Qiang, Dewen Leng, Luling Yang, Xueneng Hu, Feiyan Chen, Tinglin Zhang, Jie Gao, Zuochong Yu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. [Bifunctional biomaterials: An innovative strategy for synergistic bone tumor therapy and bone regeneration].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Huaiyuan ZhangDepartment of Orthopedics, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Yu WangDepartment of Orthopedics, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Huifen QiangChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Dewen LengDepartment of Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Luling YangDigestive Endoscopy Center, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200336, China.
Xueneng HuDepartment of Orthopedics, Jinshan Hospital, Fudan University, Shanghai, 201508, China.
Feiyan ChenDepartment of Orthopedics, Huashan Hospital, Fudan University Shanghai, 201508, China.
Tinglin ZhangChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Jie GaoChanghai Clinical Research Unit, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Zuochong YuDepartment of Orthopedics, Jinshan Hospital, Fudan University, Shanghai, 201508, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The standard treatment for osteosarcoma combines surgery with chemotherapy, yet it is fraught with challenges such as postoperative tumor recurrence and chemotherapy-induced side effects. Additionally, bone defects after surgery often surpass the body's regenerative ability, affecting patient recovery. Bioengineering offers a novel approach through the use of bioactive scaffolds crafted from metals, ceramics, and hydrogels for bone defect repair. However, these scaffolds are typically devoid of antitumor properties, necessitating the integration of therapeutic agents. The development of a multifunctional therapeutic platform incorporating chemotherapeutic drugs, photothermal agents (PTAs), photosensitizers (PIs), sound sensitizers (SSs), magnetic thermotherapeutic agents (MTAs), and naturally occurring antitumor compounds addresses this limitation. This platform is engineered to target osteosarcoma cells while also facilitating bone tissue repair and regeneration. This review synthesizes recent advancements in integrated bioactive scaffolds (IBSs), underscoring their dual role in combating osteosarcoma and enhancing bone regeneration. We also examine the current limitations of IBSs and propose future research trajectories to overcome these hurdles.

Indexed as

Bone regenerationChemotherapyIntegrated bioactive scaffoldsOsteosarcomaSurgery

Identifiers

PMID39444939
PMCPMC11497376

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.